NIVF: financial statements from SEC — TradeAlmanac

NIVF

NewGenIvf Group Limited: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	31 Dec 2025	31 Dec 2024	31 Dec 2023	31 Dec 2022	31 Dec 2021
Revenue	5M	5M	5M	6M	4M
Cost of revenue	4M	4M	3M	4M	3M
Gross profit	955,846	2M	2M	2M	1M
Selling, general and administrative	10M	3M	2M	1M	801,329
Operating expenses	12M	3M	2M	1M	826,022
Operating income	−11M	−1M	42,242	398,705	198,758
Interest expense	616,423	778,656	46,179	—	—
Pre-tax income	10M	−960,807	108,418	343,988	156,184
Income tax	—	−486,706	—	208,141	294,716
Net income	10M	−524,643	130,193	458,667	−533
Earnings per share	214.73	−4,408.76	13,019.30	4.72	0.00
Earnings per share, diluted	3.04	−4,408.76	13,019.30	4.72	0.00
Weighted average shares	46,009	119	10	28,797	560,000
Weighted average shares, diluted	3M	119	10	28,797	560,000

Balance sheet

Metric	18 Aug 2026	31 Dec 2025	31 Dec 2024	31 Dec 2023	31 Dec 2022	31 Dec 2021	31 Dec 2020
Cash and equivalents	—	758,621	457,740	54,104	27,556	28,764	106,192
Receivables	—	166,531	49,245	9,374

Cash flow

Metric	31 Dec 2025	31 Dec 2024	31 Dec 2023	31 Dec 2022	31 Dec 2021
Operating cash flow	−11M	−8M	−2M	2M	1M
Depreciation and amortisation	188,109	19,502	31,173	100,533	166,709
Share-based compensation

Amounts in USD unless stated otherwise. Data: US exchange trading and company filings with the regulator